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Capsule summary: 54 
Deep-immunophenotyping of the circulatory T cell compartment using mass cytometry and 55 
unsupervised clustering analysis, identifies phenotypic and functional differences in patients with 56 
atopic dermatitis (AD) and psoriasis, highlighting the stronger systemic component associated 57 
with AD. 58 
 59 




ANOVA: Analysis of variance 64 
AD: Atopic dermatitis  65 
HD: Healthy donors 66 
F: Functional 67 
P: Phenotypic 68 
DMSO: dimethyl sulfoxide 69 
FOXP3: forkhead box P3 70 
CCR: C C chemokine receptor 71 




TNF: tumor necrosis factor 72 
IFN: interferon 73 
GM-CSF: granulocyte-macrophage colony-stimulating factor 74 
MIP: macrophage inflammatory protein 75 
MR-1: MHC-related protein 1 76 
Th: T helper  77 
CYTOF: Cytometry by time of flight  78 
MAIT:  mucosal-associated invariant T  79 
tSNE:  t-Distributed Stochastic Neighbor Embedding  80 
PSO: psoriasis 81 
RA: rheumatoid arthritis 82 
TRM: Tissue resident memory T  83 
 TCM: central memory T 84 
 TEM: effector memory T 85 
TRcM:  recirculating memory T  86 









To the Editor 92 
 93 
Atopic dermatitis (AD) and psoriasis are T cell-mediated, chronic inflammatory skin conditions, 94 
which are increasingly recognized as systemic rather than localized cutaneous diseases (1, 2). 95 
Hence, a deeper understanding of the phenotypic and functional features of the circulatory T-cell 96 
compartment may offer novel insights into their pathogenesis, generate opportunities for novel 97 
targeted therapies, as well as, aid in the identification of potential biomarkers.  We and others have 98 
previously performed fluorescence-based immunophenotyping of circulatory T cells in psoriasis 99 
and AD (1), and an earlier comparative study highlighted distinctive features of systemic activation 100 
in T cells of AD patients (3). Here, we exploit the increased dimensionality of mass cytometry 101 
(cytometry by time of flight, CyTOF),  which is  able to detect over 50 different heavy metal 102 
isotopes simultaneously, and the power of unsupervised analytical methods, to profile and compare 103 
phenotypic and functional features of circulating CD4+ and CD8+ T cells of  AD (n=15), psoriasis 104 
(n=19), and healthy donors (HD, n=9). 105 
PBMCs were obtained from a total of 43 age-matched subjects (Fig. E1A), recruited into an 106 
observational clinical study approved by the London Bridge Research Ethics committee. 107 
Demographics and clinical characteristics of the subjects are shown in Table E1. A description of 108 
the methods is provided in the Methods section in this article’s Online Repository at 109 
www.jacionline.org.   110 
We ran a Phenotypic (P) panel, including 42 lineage, differentiation, activation, trafficking and 111 
homing markers, and a Functional (F) panel, including 27 phenotypic surface markers and 15 112 
intracellular functional markers (e.g. cytokines, chemokines) (Table E2). Frequency of manually 113 
gated CD4+ and CD8+ T cells, as well as other major cell populations (Fig. E1B), did not 114 
significantly differ among AD, psoriasis and HD (Fig. E1C). Appling  unsupervised clustering 115 
analysis to gated CD4+ and CD8+,  we identified 144 cell clusters: 34 cell clusters in the CD4+ P 116 




and 31 in the CD8+ P dataset, as well as 51 in the CD4+ F and 29 in the CD8+ F dataset (Fig. 117 
E1A, Fig. E2A). Each dataset was visualized by applying a dimensionality reduction method, i.e. 118 
t-Distributed Stochastic Neighbor Embedding (tSNE) and coloring the cells according to the 119 
clusters they were assigned to. Clusters were curated and assigned to standard immune subsets, 120 
based on the mean expression of subset-defining markers, such as CD161 and Vα7.2 for mucosal-121 
associated invariant T (MAIT) cells and CD103 for Recirculating memory T cells (TRcM) (Fig. 122 
E2A, Fig. E3-6). 123 
We compared the average clusters’ frequency within each of the four datasets and the means for 124 
each cytokine/chemokine in two-way comparisons applying False Discovery Rate (FDR) 125 
correction for multiple testing. Overall, we detected statistically significant differences (p-adj < 126 
0.05) in 68 two-way comparisons (Table E3). Three cell populations were of particular interest: 127 
MAIT cells, TRcM CD8+ T cells, and CD49+ CD4+ Regulatory T (TReg ) cells. 128 
Clusters CD8+P13 and CD8+ F14 displayed the hallmark features of MAIT cells, with high levels 129 
of Vα7.2 and CD161 (Fig. 1A). Frequencies of MAITs were significantly reduced in psoriasis 130 
patients versus HD and AD (Fig. 1B). This is in keeping with the reported reduction in circulating 131 
MAITs in immune-mediated and autoimmune diseases  such as RA,  where they are 132 
correspondingly enriched in the synovial fluid, possibly contributing to disease pathogenesis either 133 
directly, or through recruitment of other cells (4). Thus, MAIT cells might preferentially migrate 134 
from blood into the inflamed skin, and they have been indeed identified in lesional psoriatic skin 135 
(5), although it is not known whether they are increased in inflamed versus healthy skin.  136 
The vast majority of MAIT cells produced MIP1-β and TNF (Fig. 1C, E7A), with AD producing 137 
significantly more than psoriasis (Fig. 1D, E7B), suggesting that they are more activated in allergic 138 
disease. As MAIT cells respond to MR-1-restricted vitamin B2 derivatives, and Staphylococcus 139 
aureus is equipped with the specific biosynthetic pathway for their production, their increased 140 
activation in AD might be linked to S. aureus infection. 141 




Three CD8+ cell clusters identified in both Phenotypic and Functional dataset, i.e. i) CD8+ 142 
P24/CD8+ F28, ii) CD8+ P15/CD8+ F18, and iii) CD8+ P27/CD8+ F29,  were characterized by 143 
the simultaneous expression of low levels of CCR7, and either skin-(CLA+, CCR4+, CCR10+) or 144 
gut- (Intb7, CD49d as well as CCR9) homing markers (Fig. 1E). Features of these clusters broadly 145 
map to effector memory T cells; both skin and gut-homing clusters expressed CD103, suggesting 146 
that they previously resided  in the tissue, as recently reported  for CD4+ CD103+ cells by Klicznik 147 
et al (6). They may be en-route back from their target organ where they had acquired CD103 148 
expression through exposure to TGF-β of epithelial origin (6). Hence, we tentatively named them 149 
TRcM. TRcM were functionally characterized by widespread production of TNF and sizable 150 
expression of IL-2, GM-CSF and IL-22 (Fig. 1F and E7C). Frequencies of all  TRcM clusters were 151 
significantly increased in AD as compared to HD and psoriasis (Fig. 1G and E7D), confirming 152 
and expanding recent studies showing increased  recirculation, frequency and activation of skin-153 
homing T cells in AD (7). This is in keeping with the sequelae of non-cutaneous atopic 154 
manifestations known as atopic march. Of particular interest is the increase in gut-homing TRcM, 155 
as AD often precedes the development of food allergy.  156 
 Skin- homing TRcM (F28) were the major IL-22 producer within CD8+T cells (Fig. 1H), with AD 157 
patients producing significantly more IL-22 than HD (Fig. 1I). Interestingly, IL22 production in 158 
Skin- homing TRcM, correlated with AD severity (Fig. 1J),  highlighting the importance of IL-22 159 
in the pathophysiology of AD, and in line with the beneficial effect of IL-22 blockade in AD 160 
clinical trials (8). 161 
Lastly, three clusters within the CD4+ Phenotypic dataset displayed hallmarks of TReg cells: 162 
CD45RA+CD45RO- FOXP3+ CD25+ CD127- naïve TReg (P10), CD45RA-, CD45RO+, CD95+, 163 
FOXP3+ CD25+ CD127- CLA+  skin-homing memory TRegs (P14),  and   CD45RA-, CD45RO+, 164 
CD95+, FOXP3+ CD25+ CD127- CD49d+ memory TReg (P22) (Fig. 2A).  165 




Frequencies of P22 memory TReg were significantly reduced in AD versus psoriasis, with a 166 
downward trend versus HD (Fig. 2B). Earlier studies have reported increased frequency of TReg in 167 
the blood of AD patients (9), although less phenotypic markers have been used, raising the question 168 
of whether they were bona fide TRegs or a mixed population comprising activated-effector T cells 169 
and TReg. Discrepancies among studies could also be explained by their dynamic fluctuation 170 
between the blood and skin compartment potentially driving disease relapses and remissions. This 171 
notion is supported by a previous report of  Treg frequecny correlating with disease severity (3) 172 
although we did not find this relationship in our data (data not shown). To validate our findings, 173 
we combined clusters P10, P14 and P22 and performed a zoomed-in tSNE analysis (Fig. E7E). 174 
While CD45RA, CCR4 and CLA clearly separated TRegs into three clusters (Fig. E7E), the 175 
presence of additional cell subsets within cluster P14 was also evident, with dichotomous 176 
expression of CLA and CD49d in P22 and P14(Fig. E7F). Thus, we applied manual gating to 177 
further phenotype memory TReg based on their expression of CLA, CD49d and CCR6. (Fig. 2C). 178 
AD patients displayed an overall reduced frequency of non-skin homing CD49d+ TReg, irrespective 179 
of CCR6 expression, as compared to psoriasis, and with a downward trend versus HD, mirroring 180 
the observed decrease in cluster P22. Moreover, CCR6+TReg within skin-homing CLA+ cells were 181 
also significantly reduced in AD versus HD, while CCR6-TReg within skin-homing CLA+ cells 182 
were significantly increased in psoriasis versus AD and HD (Fig. 2C). In contrast, non-TReg 183 
memory CLA+CCR6+ cells were significantly increased in AD as compared to HD and psoriasis. 184 
Here, we have provided an exhaustive description of the circulatory T cell compartment, 185 
highlighting phenotypic and functional differences in patients with AD and psoriasis.  186 
Unsupervised analysis has overcome the bias of subjective gating by increasing resolution and 187 
capturing unexpected combinations of markers, e.g. identifying cell types that escape standard 188 
classification strategies, e.g. TRcM expressing CD103. 189 




Our data highlight the stronger systemic component associated with AD, as compared to psoriasis, 190 
and provide a resource to further investigate the phenotypic and functional features of the two 191 
major inflammatory skin diseases. Future studies are needed to delineate the relationship of the 192 
specific cell populations in blood and skin, explore their pathogenic potential, and ultimately assess 193 
the utility of these findings for the identification of prognostic and/or predictive biomarkers, as 194 
well as potential novel therapeutic targets. Our study proposes MAIT cells as of potential 195 
pathogenic relevance for skin inflammation and calls for further studies aimed at assessing their 196 
functional capacity in blood and skin of patients with inflammatory skin diseases.  IL-22-197 
producing skin-homing TRcM may be an attractive candidate for future studies to identify 198 
biomarkers of response to IL-22 blockade in AD. Finally, this study highlights the utility of blood 199 
and the use of profiling T cells by trafficking receptor expression patterns for discovery in the 200 
context of tissue-specific immunological diseases.  201 
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Figure Legends 277 
Figure 1: Mucosal-invariant T-cells (MAIT) and Recirculating memory CD8+ T cells in skin 278 
disease 279 
(A) Heatmap of mucosal-invariant T (MAIT) cells, within CD8+ Phenotypic and Functional 280 
datasets. (B) Frequency of MAIT cells in atopic dermatitis (AD), healthy donor (HD) and psoriasis 281 
(PSO). (C) MIP-1β, TNF-α, IFN-γ, GM-CSF, IL-2 and IL-17A production in MAIT cells, 282 
visualized in tSNE. (D) Cytokine production in MAIT cells, in AD, HD and PSO. (E) Heatmap of 283 
recirculating memory T cells (TRcM), within the CD8+ Phenotypic and Functional datasets. (F) 284 
TNF-α, GM-CSF, IL-2 and IL-22 production in TRcM, visualized in tSNE. (G) Frequency of TRcM 285 
in AD, HD and PSO. (H) Representative dot plots of AD, HD and PSO depicting expression of 286 
IL-22 and GM-CSF in manually gated cells (red) within skin-homing TRcM (bottom) compared to 287 
total CD8+ T cells (top). (I) IL-22 and GM-CSF production in skin-homing TRcM, in AD, HD and 288 
PSO. (J) Correlation between IL-22 production in skin =homing TRcM and disease severity in AD 289 
. Relative cell frequency (B, G) or cytokine expression (D, I) are shown, with circles representing 290 
individual samples, and box and whiskers denoting minimum and maximum values.  291 
*p-adj<0.05; **p-adj<0.01 292 
 293 
Figure 2. Regulatory CD4+ T cells in skin disease. 294 
(A) Heatmap of Regulatory T cells (TRegs), within the CD4+ Phenotypic dataset. (B) Frequency 295 
of TRegs in atopic dermatitis (AD), healthy donor (HD) and psoriasis (PSO) samples. 296 
Relative cell frequency is shown, with circles representing individual samples, and box 297 
and whiskers denoting minimum and maximum values. (C) Manual gating strategy to 298 
obtain Tregs subsets. Differences in cell frequencies were assessed by one -way ANOVA 299 




followed by Dunn test for multiple correction, ****p-adj<0.0001, ***p-adj<0.001, **p-300 









Supplementary Material for Online Repository 
 
T-cell phenotyping uncovers systemic features of atopic dermatitis and 
psoriasis. 




Nine HD, 19 psoriasis and 15 AD patients, recruited at tertiary referral centers at Guy’s and St 
Thomas’ Hospital, Queen Elizabeth Hospital and West Middlesex University Hospital, were 
included in this study. Patients were not receiving any conventional or biological systemic therapy 
at the time of sampling. Healthy donors were nominally healthy at the time of sample collection 
and did not report any allergic or auto-immune disease. Full demographics can be found in Table 
E1. The study was conducted in accordance with the Declaration of Helsinki Principles, with 
written informed consent obtained from each volunteer and approved by the London Bridge 
Research Ethics committee (Reference 11/LO/1962). One additional healthy donor was recruited 
at SIgN, A*STAR (IRB number: NUS-IRB-09-256) as internal control to be run with each batch. 
 
PBMCs isolation and cryopreservation  
PBMCs were isolated by blood centrifugation on a density gradient (Ficoll-Plaque Plus, VWR). 
Cells were viably frozen in RPMI 1640 (Life Technologies) supplemented with 11.25% HSA 
(Gemini Bio-Products)/10% DMSO (Sigma), stored in liquid nitrogen and shipped all together to 
SIgN A*STAR in a shipper tank filled with liquid nitrogen. PBMCS from one additional healthy 
donor to be used as internal control (IC) were isolated at the SIgN, A*STAR and cells were 
2 
 
cryopreserved in 90% fetal bovine serum (FBS) (Life Technologies) plus 10% DMSO (MP 
Biomedicals).  
 
PBMCs stimulation and staining  
PBMCS were processed in 7 batches, each including the IC and samples from each BioDiP group 
(HD, AD and Pso). Cryopreserved cells were thawed, washed with pre-warmed RPMI 1640 
supplemented with 1% FBS, 1X Penicillin/Streptomycin/L-glutamine, 1% 1M HEPES and 1X β-
mercaptoethanol (all Life Technologies), and rested overnight at 37°C. Next, cells were washed 
and split into two aliquots of up to 3 x 106 cells each for staining with the Phenotypic Panel, 
including 42 surface and intracellular markers, and the Functional Panel, including 27 phenotypic 
markers and 14 cytokines (Table E2). For both panels, staining of surface markers (Surface I in 
Table E2) that are weakly expressed or are downregulated during polyclonal stimulation, was 
carried out in 96-well round bottom plates at 37°C for 30 minutes. Next, cells were either left 
untreated (Phenotypic Panel) or stimulated with 150 ng/ml phorbol-12-myristate-13-acetate 
(PMA) and 1 µM ionomycin (Sigma-Aldrich) in the presence of monensin and Brefeldin A (all 
eBioscience) for four hours for the detection of intracellular cytokines (Functional Panel). After 
incubation, cells were washed twice in cold PBS, incubated on ice with 100 µM cisplatin (Sigma-
Aldrich) for 5 minutes for Live/Dead staining, washed with staining buffer and stained with 
fluorophore-tagged antibodies for 30 minutes on ice (Surface II, Table E2). Next, cells were 
washed twice in staining buffer and stained with metal isotope-labeled surface antibodies (Surface 
II, Table E2) for 30 minutes on ice. 
Cells for the Phenotypic Panel were then washed, fixed in Foxp3 Transcription Factor 
Fixation/Permeabilization buffer (eBioscience), washed in Permeabilization buffer (Biolegend) 
and stained with metal isotope-labeled antibodies against intracellular phenotypic markers (Intra 
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Table E2, Phenotypic Panel), each step carried out on ice for 30 minutes. Next, cells were 
incubated with metal isotope-conjugated streptavidin for 10 minutes, washed and fixed in 2% 
paraformaldehyde (PFA; Electron Microscopy Sciences) at 4°C, overnight. Next day, cells were 
washed twice with 1X perm buffer, once with PBS, and incubated with cellular barcodes for 30 
minutes (Surface III, Table E2). Next, cells were washed once with 1X perm buffer, incubated in 
staining buffer for 10 minutes on ice, and DNA was labelled with 250 nm iridium intercalator 
(Fluidigm Corporation) in PBS-2% PFA at room temperature for 20 minutes. Finally, cells were 
washed twice with staining buffer, re-suspended in 90% FBS + 10% DMSO in a 96-well round 
bottom plate and stored immediately at -80°C, prior to CyTOF acquisition. 
Following Surface II staining, cells for the Functional Panel were washed twice with staining 
buffer, once in PBS and fixed in 2% PFA with at 4°C overnight. Next day, cells were washed twice 
with 1X perm buffer and stained with intracellular antibodies (Intra, Table E2, Functional Panel) 
on ice for 30 minutes. Next, cells were washed, labelled with cellular barcodes and DNA 
intercalator, cryopreserved and stored until CyTOF acquisition, as described for the Phenotypic 
Panel. 
Cytometry by-time-of-flight (CYTOF) 
Prior to CyTOF acquisition, cryopreserved stained cells from each batch were thawed, washed 
twice and re-suspended in staining buffer. Aliquots of cells from all samples within a batch were 
pooled and filtered through a 0.35 µm strainer into a 5 ml polystyrene tube. Pooled, filtered cells 
were washed twice in water before final re-suspension in water at 0.5 x 106 cells/ml. EQ Four 
Element Calibration Beads (Fluidigm Corporation) were added to a concentration of 1% prior to 





Data cleaning and manual gating 
Raw data were manually cleaned and curated. Patient AD6 was excluded from the overall analysis 
for low cell viability. Samples run in batch 1 were excluded for unsupervised analysis of the 
Phenotypic Panel due to suboptimal staining (Table E1). Data were normalized with beads and 
files corresponding to the same batch were concatenated, using the Fluidigm CyTOF software. 
Obvious dead cells were removed to facilitate debarcoding. Manual debarcoding using Infinicyt 
software was performed to obtain the individual FCS files for each sample. Manual gating to 
identify CD4+ and CD8+ T populations for each sample was performed using Cytobank (Fig. 
E1B). From this step onward, each panel (Phenotypic and Functional) and each manually gated T 
cell compartment (CD4+ T, CD8+ T) was pre-processed, processed for clustering and analyzed 
independently, resulting in 4 different datasets, Functional CD4, Functional CD8, Phenotypic CD4 
and Phenotypic CD8. 
 
T cell datasets pre-processing, QC and clustering 
For each dataset, 10,000 CD4+T or CD8+T cells were randomly selected from each sample (or 
the entire sample was used if it contained less than 10,000 cells) and merged into a single FCS file. 
Marker expression for all markers except Time and Event length, was asinh-transformed using a 
cofactor of 5. In order to minimize batch differences, a normalization step was applied to both 
Panels. For the Functional Panels, CD4+ and CD8+ T-cells were normalized dividing the 
expression of each marker (except Time, Event length and DNA) by the mean of that marker in 
the intact live cells from the corresponding batch. In the Phenotypic Panel, CD4 and CD8 T-cells 
were normalized dividing the expression of each marker by the 99th percentile of that marker in 
the intact live cells from the corresponding batch. Independent clustering for each of the 4 datasets 
was performed using the clustering algorithm PhenoGraph in its python implementation (1). The 
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specific marker combinations, and values of the parameter k, the number of nearest neighbor used 
to build the similarity graph, used for each dataset are listed in Table E4. 
Quality of normalization and clustering was assessed by visualizing the frequency of each cluster 
in the IC and 9 HD. Minimal instability was observed among the IC across different batches, while 
variability among HD was much larger, as expected for true biological variation, which we 
confirmed by comparing the coefficient of variation of  IC and HD (p<0.001 for all 4 datasets) 
(Fig. E2B and data not shown). 
 
Dimensionality reduction, visualization and cluster interpretation 
Dimensionality-reduction for visualization purposes was performed using the t-Distributed 
Stochastic Neighbor Embedding algorithm (2) as implemented in the R package Rtsne. 
Representative tSNE plots for each of the 4 datasets were built by randomly selecting 60.000 cells 
from each dataset. The perplexity parameter was set to 30. The median tSNE1 and tSNE2 
coordinates of the cells belonging to each cluster are shown as black dots and labeled by their 
cluster ID. To enhance visualization, cells were colored according to the clusters they were 
assigned to. As expected, cells belonging to a specific, colour-coded cluster were found on adjacent 
coordinates in the tSNE plots (Fig E2A). Additional tSNE plots representative for specific clusters 
were created by randomly selecting 30.000 cells belonging to those clusters. The perplexity 
parameter was set to 30 and only cytokines were used to generate the tSNE plots.  
Each cluster was manually analyzed and assigned to standard immune subsets, based on the mean 
expression of subset-defining markers, such as CD161 and Vα7.2 for mucosal-associated invariant 
T (MAIT) cells and CD103 for Recirculating memory T cells (TRcM) (Fig. E3A). To confirm that 
the markers used were reliable discriminators for the indicated populations, we combined the 
profile of selected clusters with the tSNE projection and colour-graded the expression of the most 
6 
 
defining markers for each cell population on the tSNE plot (Fig E3B). As expected, maximal 
expression of the defining markers co-localized with the tSNE coordinates of the respective cluster 
shown in Fig. E2A.  Moreover, visual inspection of density dot plots further confirmed that 
identified cell cluster were real biological entities, when compared with a negative control 
population cluster CD8+ F20. 
 
IgE Measurement  
IgE were measured in the serum of AD patients using Human IgE Ready-Set-GO from Affymetrix 
according the manufacturer’s instructions.  
 
Statistical Analysis 
Frequencies per sample were computed for all clusters in each of the four datasets. Variability 
within IC and HD was evaluated by calculating coefficient of variation (CV) for each cluster within 
both groups and performing Mann-Whitney U test comparison for each dataset.  Mean normalized 
expression values for each cytokine per sample in each cluster were also computed for the 
Functional Panel dataset. Statistical significance for differences in frequencies and mean 
normalised expression across groups was computed using a linear mixed effects model based on 
the following formula (in the coding language R): 
expression/frequency ~ study_group * visit_number + age + sex + ethnicity + batch + 
(1|subject_ID) 
That is, where the subject ID represents the random effect variable, and the other variables 
(including the interaction term between study_group and visit_number) are fixed effects. 
Models were fitted using the R package lmer and contrasts of interest were extracted using the 
function glht from the R package multcomp. This method was chosen to account for the fact that 
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multiple samples were coming from the same donor and as there were missing samples for some 
of the time points (where a paired test would have required to drop out many samples). p-values 
were corrected for the number of clusters (frequency) or cluster-cytokine pairs (mean normalised 
expression) tested using the Benjamini-Hochberg procedure. For manually gated populations 
differences were assessed by one-way ANOVA followed by Tukey’s  test for multiple correction. 
Correlation between IL-22 production and disease severity in AD patients, measured by SASSAD, 
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Supplementary Figure Legends 
 
Figure E1: T cell profiling in inflammatory skin disease 
(A) Experimental workflow for the analysis of CD4+ and CD8+ T cells of atopic dermatitis (AD), 
healthy donor (HD) and psoriasis (PSO) patients by mass-cytometry. PBMCs were stained for 
phenotypic markers (Phenotypic Panel) or stimulated with PMA/Ionomycin and stained for 
cytokine production (Functional panel). Four datasets were obtained by pooling manually gated 
CD4+ or CD8+ cells from each experiment and performing unsupervised clustering analysis. 
Differential analysis of frequencies and cytokine expression levels was then performed. (B) Gating 
strategy used to manually identify major cell populations within PBMCs samples. Representative 
plots shown are from the Phenotypic panel. (C) Pie charts showing mean percentages of main 
lymphocyte populations within CD45+ cells identified in the Phenotypic panel in AD, HD and 
PSO.  
 
Figure E2: Evaluation of clusters frequency within healthy donors and internal control 
(A) tSNE plots of colour-coded T cell clusters within CD4+ and CD8+ T cells, identified in the 
Phenotypic and Functional panels. Labelled black dots represent the centroid (based on median) 
of the corresponding cluster. (B) Evaluation of cluster frequency within healthy donor and Internal 
control. Bar-plots of relative cluster frequency of 9 healthy donors (HD) and one internal control 
(IC) run each time, within CD4+ Phenotypic, CD4+ Functional, CD8+ Phenotypic, and 






Figure E3: Cell clusters identified in the Functional CD8 dataset 
(A) Marker analysis and attribution of the 29 clusters identified within the CD4+ Phenotypic 
dataset to standard cell populations. Normalized expression of all cells assigned to each cluster is 
represented by colors in the heatmap, and non-normalized raw values are shown as histograms. 
(B) MAIT and Recirculating Memory T cells identified within the CD8+ Functional dataset are 
visualized on tSNE plot coloured using normalized values of selected markers (left), and as dot-
plots in black (right). Cluster F20, shown in blue, is the negative control. 
 
Figure E4: Cell clusters identified in the CD4+ Functional dataset  
Marker analysis and attribution of the 51 clusters identified within the CD4+ Functional dataset to 
standard cell populations. Normalized expression of all cells assigned to each cluster is represented 
by colours in the heatmap, and non-normalized raw values are shown as histograms. 
 
Figure E5: Cell clusters identified in the CD4+ Phenotypic dataset   
Marker analysis and attribution of the 34 clusters identified within the CD4+ Phenotypic dataset 
to standard cell populations. Normalized expression of all cells assigned to each cluster is 
represented by colours in the heatmap, and non-normalized raw values are shown as histograms. 
 
Figure E6: Cell clusters identified in the CD8+ Phenotypic dataset   
Marker analysis and attribution of the 31 clusters identified within the CD8+ Phenotypic dataset 
to standard cell populations. Normalized expression of all cells assigned to each cluster is 





Figure E7. MAIT, Recirculating memory CD8+ T and T regulatory CD4+ T cells in 
inflammatory skin disease 
A) tSNE visualization of cytokine expression in Functional CD8+ cluster F14 using pooled cells 
from AD, HD and psoriasis. (B) Cytokine production in cluster F14, in AD, HD and psoriasis. (C) 
tSNE visualization of cytokine and PD-1 expression in the Functional CD8+ cluster F28 using 
pooled cells from AD, psoriasis and HD.  (D) Box plot showing frequency of TRcM clusters   F18, 
F29 and F29 in the Functional CD8+ dataset. (E) TRegs in clusters P10, P14 and P22 in the CD4+ 
Phenotypic dataset were merged and coloured by cluster, or according to the raw expression of the 








Table E1 Demographics and clinical data 







AD1 Mixed 18 M not known Generalised;flexural 
pattern 











Panel)   
AD2 Black 25 M Childhood Follicular/papular 
phenotype; extensor 
pattern 
not known Asthma, Allergic 
Rhinocongintivitis 




Panel)   
AD3 White 26 M Childhood Generalised;flexural 
pattern 









Panel)   
AD4 White 50 M Childhood Generalised;flexural 
pattern 
not known Asthma, Allergic 
Rhinocongintivitis, 
Food  allergies 
not known 83 ± 3   
AD5 White 32 M Childhood Generalised;flexural 
pattern 
not known None not known 2722 ± 50   
AD6 White 59 F Childhood Generalised; flexural 
prominence  
SASSAD 31 Asthma, Allergic 
Rhinocongintivitis 
not known 36292 ± 155 Excluded from 
overall analysis 
for low cell 
viability 
AD7 Black 57 F Childhood Generalised;flexural 
pattern; hand and foot 
eczema  
SASSAD19 None S.aureus 
(abscesses) 
1205 ± 15   
AD8 White 47 M Childhood Generalised;flexural 
pattern; hand and foot 
eczema  





5243 ± 175   
AD9 White 49 M Childhood Generalised;flexural 
pattern  





1118 ± 58   
AD10 White 35 M not known Generalised;flexural 
pattern 
not known Asthma, food allergies  HSV (eczema 
herpeticum) 
5452 ± 55   
AD11 White 60 M Adult Generalised;flexural 
pattern; hand eczema  
SASSAD17 Metals allergy not known 243 ±4   
AD12 Black 40 M Childhood Generalised;flexural 
pattern 
SASSAD 20 Asthma, Allergic 
Rhinocongintivitis 
not known 1318 ± 36   
AD13 Asian 30 M not known Generalised;flexural 
pattern; hand  eczema  
SASSAD 15  Allergic 
Rhinocongintivitis 
S.aureus 757 ± 5   
AD14 Asian 65 M not known Generalised;flexural 
pattern 





6516 ± 172   
AD15 Asian 36 M not known Generalised;flexural 
pattern; hand  eczema  
SASSAD 15 None S.aureus 17654 ±724   
PSO1 White 27 M Teenager Plaque-psoriasis PASI 10.5 Psoriatic arthritis not applicable not 
applicable 




Panel)   
PSO2 White 48 M Adult Plaque-psoriasis PASI 21.2 none not applicable not 
applicable 
  
PSO3 White 40 M Childhood Plaque-psoriasis PASI 10.2 none not applicable not 
applicable 
  
PSO4 White 37 F Childhood Plaque-psoriasis PASI 23.3 none not applicable not 
applicable 
  
PSO5 White 37 M Adult Plaque-psoriasis PASI 12.8 none not applicable not 
applicable 
  
PSO6 White 50 M Adult Plaque-psoriasis PASI 33.4 liver disease not applicable not 
applicable 
  
PSO7 White 53 F Teenager Plaque-psoriasis PASI 14.1 none not applicable not 
applicable 
  
PSO8 White 58 F Childhood Plaque-psoriasis PASI 9.9 none not applicable not 
applicable 




Panel)   
PSO9 White 47 M Teenager Plaque-psoriasis PASI 17.3 none not applicable not 
applicable 
  
PSO10 White 50 M Adult Plaque-psoriasis PASI 15.3 Hyperthension, 
hypercolerestemia 
not applicable not 
applicable 
  
PSO11 Asian 19 M Childhood Plaque-psoriasis PASI 22.7 none not applicable not 
applicable 
Excluded  from 
the analysis of 
Phenotypic 
markers 
PSO12 Asian 37 M Childhood Plaque-psoriasis PASI 17.9 none not applicable not 
applicable 
  
PSO13 White 48 M Adult Plaque-psoriasis PASI 12.6 none not applicable not 
applicable 
  
PSO14 White 45 M Teenager Plaque-psoriasis PASI 25 none not applicable not 
applicable 
  
PSO15 Asian 28 M Teenager Plaque-psoriasis PASI 35.5 none not applicable not 
applicable 
  
PSO16 White 36 F Adult Plaque-psoriasis PASI 17.6 
 
not applicable not 
applicable 
  
PSO17 White 61 F Adult Plaque-psoriasis PASI 13.5 asthma not applicable not 
applicable 
  
PSO18 White 33 F Adult Plaque-psoriasis PASI 13.7 asthma not applicable not 
applicable 
  
PSO19 White 35 F Adult Plaque-psoriasis PASI 26.7 none not applicable not 
applicable 
  
HD1 White 50 M not 
applicable 
not applicable not 
applicable 
not applicable not applicable not 
applicable 




markers   




Panel)   
HD3 White 32 M NA NA NA NA NA NA   
HD4 White 28 F NA NA NA NA NA NA   
HD5 White 53 F NA NA NA NA NA NA   
HD6 White 48 M NA NA NA NA NA NA   
HD7 White 31 M NA NA NA NA NA NA   
HD8 White 24 M NA NA NA NA NA NA   
HD9 White 32 M NA NA NA NA NA NA   
           
 
 
Table E2 Staining panels   
         








































house  Surface III   113 Cellular Barcode Synthesized in house  Surface III 
89 CD45 
Fluidigm 
(HI30) Surface II   89 CD45 Fluidigm (HI30) Surface II 
112/114 Qdot800-CD14 
Invitrogen 
(TuK4) Surface II   112/114 Qdot800-CD14 Invitrogen (TuK4) Surface II 
115 CD57 
Biolegend 
























(UCHT1) Surface II   140 CD3 Biolegend (UCHT1) Surface II 
141 HLA-DR 
Biolegend 
(L243) Surface II   146 CD8α Biolegend (SK1) Surface II 
142 CLA 
Biolegend 
(HECA-452) Surface II   147 CD45RA Biolegend (HI100) Surface I 
143 CD38 
Biolegend 
(HIT2) Surface II   148 CLA Biolegend (HECA-452) Surface II 
144 Granzyme B 
Abcam (CLB-
GB11) Surface II   149 CD4 Biolegend (SK3) Surface I 
145 CD62L 
BD Biosciences 
(DREG-56) Surface II   150 CD103 eBioscience (B-Ly7) Surface I 
146 CD8α 
Biolegend 
(SK1) Surface II   152 CD25 Biolegend (M-A251) Surface I 
147 CD45RO 
Biolegend 
(UCHL1) Surface II   153 CD107a BD Biosciences (H4A3) Surface II 
148 Vδ2 Biolegend (B6) Surface II   154 CD40L eBioscience (24-31) Surface II 
149 CD4 
Biolegend 
(SK3) Surface II   155 CTLA-4 BD Biosciences (BNI3) Surface II 
150 CD103 
eBioscience (B-
Ly7) Surface II   156 Vδ2 Biolegend (B6) Surface II 
151 CCR4 
R&D Systems 
(205410) Surface II   158 CD56 BD Biosciences (NCAM16.2) Surface II 
152 Ki-67 
BD Biosciences 
(B56) Intra   159 Integrin β7 Biolegend (FIB504) Surface I 
153 CD49a 
Biolegend 
(TS2/7) Surface II   161 CCR9 Biolegend (L053E8) Surface I 
154 CCR10 
R&D Systems 






  164 CD19 Biolegend (HIB19) Surface II 
Streptavidin 
(Secondary) Synthesized in 
house   165 Vα7.2 Biolegend (3C10) Surface I 
156 CCR7 
R&D Systems 
(150503) Surface I   166 CXCR5 BD Biosciences (RF8B2) Surface I 
157 CD27 
eBioscience 
(LG.7F9) Surface I   168 CCR2 Biolegend (K036C2) Surface I 
158 CD56 
BD Biosciences 
(NCAM16.2) Surface II   171 CCR6 Biolegend (G034E3) Surface I 
159 Integrin β7 
Biolegend 
(FIB504) Surface I   173 CCR4 R&D Systems (205410) Surface I 
160 PD-1 
eBioscience 
(eBioJ105) Intra   175 CCR5 Abcam (HEK/1/85a) Surface I 
161 
Vδ1 FITC 
(Primary) Miltenyi Biotec 
(REA173) 
Surface II 
  209 CD16 Fluidigm (3G8) Surface II 
anti-FITC 
(Secondary) Biolegend (FIT-
22)   141 IFN-γ eBioscience (4S.B3) Intra 
162 CD95 
Biolegend 
(DX2) Surface II   142 TNF-α eBioscience (MAb11) Intra 
163 CXCR3 
R&D Systems 
(49801) Surface II   143 IL-8 Biolegend (E8N1) Intra 
164 CCR9 
Biolegend 
(L053E8) Surface I   144 Granzyme B Abcam (CLB-GB11) Intra 
165 Vα7.2 
Biolegend 
(3C10) Surface I   145 IL-17F eBioscience (SHLR17) Intra 
166 CXCR5 
BD Biosciences 
(RF8B2) Surface II   151 IL-2 eBioscience (MQ1-17H12) Intra 
167 CD49d 
Biolegend 
(9F10) Surface II   157 MIP-1β BD Biosciences (D21-1351) Intra 
168 CCR2 
Biolegend 
(K036C2) Surface I   160 PD-1 eBioscience (eBioJ105) Intra 
169 CD25 
Biolegend (M-
A251) Surface II   162 IL-5 Biolegend (JES1-39D10) Intra 
170 CD161 
Biolegend (HP-
3G10) Surface I   167 IL-9 BD Biosciences (MH9A4) Intra 
171 CCR6 
Biolegend 
(G034E3) Surface II   169 IL-4 Biolegend (MP4-25D2) Intra 
172 CD45RA 
Biolegend 
(HI100) Surface II   170 IL-10 eBioscience (JES3-9D7) Intra 
173 CD19 
Biolegend 
(HIB19) Surface II   172 GM-CSF Biolegend (BVD2-21C11) Intra 
174 CX3CR1 
Biolegend 
(K0124E1) Surface II   174 IL-22 Biolegend (Poly5161) Intra 
175 CCR5 
Abcam 
(HEK/1/85a) Surface I   176 IL-17A Biolegend (BL168) Intra 
176 CD127 
Biolegend 
(A019D5) Surface II   191/193 DNA Fluidigm DNA 
209 CD16 Fluidigm (3G8) Surface II   195 CisPlatin  Sigma-Aldrich Live/dead 
191/193 DNA Fluidigm DNA   
  195 CisPlatin  Sigma-Aldrich Live/dead   
 
Table E3 Class Comparisons 
Variable Two-way 
comparisons 







AD vs HD CD8+ 
Phenotypic 
P15  0.01918 5.4545 TRcM ↑ in AD 
P27 0.04711 0.3009 TRcM ↑ in AD 
P24 0.04711 1.2636 TRcM ↑ in AD 
CD8+ 
Functional  
F18 0.03012 3.7208 TRcM ↑ in AD 
F28 0.04756 1.3014 TRcM ↑ in AD 
F29 0.04756 0.2971 TRcM ↑ in AD 
Pso vs AD CD4+ 
Phenotypic 




P15 0.00688 -4.8345 TRcM ↑ in AD 
P27 0.00688 -0.2957 TRcM ↑ in AD 
P13 0.00688 -5.3525 MAITs ↓ in Pso 
P24 0.00688 -1.2771 TRcM ↑ in AD 
P8 0.03115 3.2531   
CD8+ 
Functional  
F18 0.02473 -3.4072 TRcM ↑ in AD 
F28 0.02473 -1.3535 TRcM ↑ in AD 
F29 0.04425 -0.2861 TRcM ↑ in AD 
Pso vs HD  CD8+ 
Phenotypic  
P13 0.02057 -5.159 MAITs ↓ in Pso 
P18 0.01999 1.3257   
P3 0.02057 -11.2144   
CD8+ 
Functional 
F6 0.01198 -2.6657   
F1 0.01198 -3.0584   
Cytokine 
expression 
AD vs HD CD8+ 
Functional  
F28-IL-22 0.0346 4.6189 ↑ IL-22 Skin 
homing TRcM in 
AD 




-1.6209   
F17-IL-2 0.00076 -1.4239   
F15-IL-5 0.00076 -0.1376   
F20-IL-2 0.0016 -0.9294   
F6-IL-2 0.00189 -0.8553   
F1-IL-2 0.00189 -0.7572   
F17-IL-4 0.00331 -1.0255   
F10-IL-2 0.00413 -0.7834   
F15-GM-CSF 0.00413 -2.87   
F35-IL-2 0.00413 -0.8284   
F28-IL-2 0.00413 -2.1091   
F15-IL-2 0.00446 -1.5149   
F3-
Granzyme_B 
0.00489 -0.274   
F7-IL-2 0.00526 -0.7901   
F34-
Granzyme_B 
0.00551 -0.4253   
F26-TNFα 0.00555 -0.4811   
F17-IL-10 0.00583 -1.0828   
F3-IL-17F 0.00634 -0.3753   
F26-IL-2 0.00847 -0.9284 CD4+ T cells 
more activated 
in AD 
F26-GM-CSF 0.00859 -2.1144   
F15-IL-4 0.00905 -1.4349   
F26-
Granzyme_B 
0.00958 -0.2734   
F3-TNF 0.01183 -0.5216   
F48-GM-CSF 0.01221 -5.5909   
F11-IL-2 0.01292 -1.1134   
F19-IL-2 0.01292 -1.5154   
F34-IL-22 0.01356 -1.2253   
F40-IL-2 0.01523 -1.4544   
F28-GM-CSF 0.01745 -3.1101   
F32-IL-2 0.01745 -0.7572   
F17-TNF 0.02153 -0.4009   
F3-IL-2 0.02316 -1.4063   
F1-IL-17F 0.02316 -0.0657   
F17-GM-CSF 0.02341 -0.6456   
F26-IL-22 0.03003 -0.9507   
F21-IL-2 0.03239 -1.3264   
F36-IL-5 0.04464 -0.0782   
CD8+ 
Functional  
F14-TNFα 0.01791 -0.8907 MAITs more 
activated in AD F14-MIP1β 0.03995 -1.1912 
Pso vs HD CD4+ 
Functional  
F15-IL-4 0.01818 -1.6613 CD4+ T cells not 
over-activated 
in PSO 
F47-IFNγ 0.0293 -2.218 
F47-MIP-1β 0.0293 -0.7495 
F40-IFNγ 0.0293 -0.4006 
F28-IL-4 0.0293 -1.849 
F31-IFNγ 0.0293 -0.6983 
F44-MIP-1β 0.04397 -0.6579 
F44-GM-CSF 0.04397 -1.113 
 
Table E4 Markers used for clustering 
Clustering markers 
Functional CD4 dataset Functional CD8 dataset Phenotypic CD4 dataset Phenotypic CD8 dataset 
147 CD45RA 147 CD45RA 172 CD45RA 172 CD45RA 
148 CLA 148 CLA 142 CLA 142 CLA 





152 CD25 155 CTLA-4 169 CD25 159 Integrinβ7 
155 CTLA-4 159 Integrinβ7 159 Integrinβ7 170 CD161 
156 Vd2 163 CD161 170 CD161 165 Va7.2 
159 Integrinβ7 165 Va7.2 165 Va7.2 166 CXCR5 
163 CD161 166 CXCR5 166 CXCR5 168 CCR2 
165 Va7.2 168 CCR2 168 CCR2 171 CCR6 
166 CXCR5 171 CCR6 171 CCR6 151 CCR4 
168 CCR2 173 CCR4 151 CCR4 175 CCR5 
171 CCR6 175 CCR5 175 CCR5 145 CD62L 
173 CCR4 154 CD40L 145 CD62L 141 HLA-DR 
175 CCR5   141 HLA-DR 147 CD45RO 
  147 CD45RO 144 Granzyme B  
K value 144 Granzyme B  152 Ki67 






Integrin) 154 CCR10 
154 CCR10 156 CCR7 
155 Foxp3  157 CD27 
156 CCR7 160 PD-1 
157 CD27 162 CD95 
160 PD-1 163 CXCR3 
162 CD95 164 CCR9 
163 CXCR3 167 
CD49d (α4 
Integrin) 
164 CCR9 174 CX3CR1 
167 
CD49d (α4 
Integrin) 176 CD127 
174 CX3CR1 
  176 CD127 
 
K value 
K=10 K=25 
 
